QIAGEN (QGEN)
(Delayed Data from NYSE)
$43.21 USD
-0.67 (-1.53%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.22 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.21 USD
-0.67 (-1.53%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.22 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
QIAGEN (QGEN) Publishes New Data on QuantiFERON TB Testing
by Zacks Equity Research
The study on QIAGEN's (QGEN) QuantiFERON-TB Gold Plus confirms the crucial role of CD8 T-cells for a broad immune assessment of TB infection.
QIAGEN's (QGEN) QCI Is Used by Danish National Genome Center
by Zacks Equity Research
QIAGEN's (QGEN) QCI Interpret offers evidence-based variant interpretation and reporting, and upholds the highest standards for data security and privacy. It also provides testing sites flexibility.
Qiagen (QGEN) Down 0.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory
by Zacks Equity Research
QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
Qiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down
by Zacks Equity Research
Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.
Qiagen (QGEN) Q1 Earnings Beat Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 8.51% and 0.09%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Solid Biosciences Inc. (SLDB) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Qiagen (QGEN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers
by Zacks Equity Research
In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.
QIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award
by Zacks Equity Research
QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact
by Zacks Equity Research
QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests
by Zacks Equity Research
Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.
QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.
Qiagen (QGEN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 12.77% and 3.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Qiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow
by Zacks Equity Research
QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.
QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails
by Zacks Equity Research
The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.
QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen
by Zacks Equity Research
QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.
QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval
by Zacks Equity Research
QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.
QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification
by Zacks Equity Research
QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.